Nicolas Chronos, MD
Cardiovascular Disease · Eatonton, GANPI 1427057165
Payments from drug & device makers
Across 897 payments — averaging $2649.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$907K
- Janssen Research & Development, LLC$669K
- Modernatx, Inc.$193K
- Akebia Therapeutics Inc$190K
- Johnson & Johnson$115K
- Regeneron$101K
- plus $202K from 36 others
What the payments were for
- Speaking & faculty fees$7920%
- Food & beverage$4,3960%
- Other$907,16399%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$792
- Barostim Neo System$186
- MitraClip$170
- SAPIEN 3 Ultra RESILIA$150
How this compares
$2,376,971 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 761 | $919,192 |
| XareltoRivaroxaban | 207 | $270,103 |
| EntrestoSacubitril/Valsartan | 204 | $228,352 |
| Repatha SureclickEvolocumab | 259 | $203,901 |
| OzempicSemaglutide | 176 | $192,965 |
| FarxigaDapagliflozin Propanediol | 180 | $167,321 |
| MounjaroTirzepatide | 120 | $132,190 |
| JardianceEmpagliflozin | 82 | $101,759 |
| JanuviaSitagliptin Phosphate | 64 | $72,212 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $40,821 |
| MultaqDronedarone Hcl | 21 | $39,561 |
| RybelsusSemaglutide | 19 | $34,985 |
| BrilintaTicagrelor | 42 | $33,096 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $32,392 |
| TrulicityDulaglutide | 30 | $28,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $10,913 | $925,602777 claims |
| Johnson & JohnsonXarelto | $115,286 | $270,103207 claims |
| NovartisEntresto | $7,921 | $228,352204 claims |
| Novo NordiskOzempic, Rybelsus | $458 | $227,949195 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $250 | $208,212245 claims |
| Lilly USA, LLCMounjaro, Trulicity | $63 | $160,561150 claims |
| Boehringer IngelheimJardiance, Tradjenta | $15,940 | $115,25794 claims |
| MerckJanuvia, Janumet, Belsomra | $178 | $88,97992 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $25,101 | $73,273102 claims |
| AbbVieLinzess, Synthroid | $12 | $28,514152 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $113 | $25,08641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Eatonton
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
- Michael MorrisAtlanta$1.1M
- Modele OgunniyiAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.